Oral Spironolactone for Female Pattern Hair Loss

Spironolactone is a prescription medication with antiandrogen activity that has been used for decades in the treatment of women with female pattern hair loss. Originally developed as a potassium sparing diuretic, spironolactone is FDA approved for conditions including heart failure, hypertension, certain forms of edema and primary hyperaldosteronism. It is also widely prescribed off label in dermatology for conditions influenced by androgens, including acne, hirsutism and female pattern hair loss.

Spironolactone is not FDA approved for hair loss. Unlike finasteride and dutasteride, spironolactone does not primarily work by blocking the conversion of testosterone into dihydrotestosterone, or DHT. Its relevance to hair loss comes largely from its ability to interfere with androgen signaling at the androgen receptor and, to a lesser extent, influence androgen production.

This distinction is especially important in women because female pattern hair loss is biologically more complex than classic male androgenetic alopecia. Many women with patterned thinning have normal blood androgen levels, and the exact role of androgens differs among patients. Spironolactone can nevertheless help stabilize progressive follicular miniaturization in selected women and can produce visible improvement in some patients. The evidence is considerably less extensive than the evidence supporting topical minoxidil, but spironolactone has become one of the most commonly used systemic treatments for female pattern hair loss in dermatologic practice.

What Is Spironolactone?

Spironolactone is a synthetic steroid medication originally developed to block the hormone aldosterone. Aldosterone helps regulate sodium, water and potassium balance. By blocking aldosterone, spironolactone causes the kidneys to excrete more sodium and water while conserving potassium. This is why spironolactone is classified as a potassium sparing diuretic.

The medication also has antiandrogen activity. It can compete with testosterone and DHT for androgen receptors in target tissues and can influence androgen production through several steroid hormone pathways. Those antiandrogen effects eventually led physicians to use spironolactone for hirsutism, hormonally influenced acne and female pattern hair loss. Aldactone is one well known brand name for oral spironolactone.

Is Spironolactone FDA Approved for Hair Loss?

No. There is currently no FDA approved oral spironolactone indication for female pattern hair loss. Its use for hair loss is off label.

Off label prescribing is legal and common when a physician determines that available evidence and clinical experience support use of a medication for a condition not included in its FDA approved labeling. Spironolactone’s FDA approved indications are nondermatologic and include cardiovascular, fluid retention and endocrine conditions. That distinction matters because there is no FDA established spironolactone dose, treatment duration or monitoring protocol specifically for female pattern hair loss.

Why Is Spironolactone Used for Female Pattern Hair Loss?

Female pattern hair loss involves progressive miniaturization of susceptible scalp follicles. Over time, terminal hairs become finer, shorter and less cosmetically visible. In men, the role of DHT and androgen receptor signaling in this process is well established. In women, the biology is less uniform.

Some women have evidence of androgen excess. Others have completely normal circulating testosterone and other androgen measurements yet develop the same progressive follicular miniaturization. This is one reason the term female pattern hair loss is generally preferable to simply assuming every woman has the same androgen driven disease seen in men. Spironolactone is used because androgen signaling appears to contribute to follicular miniaturization in at least a meaningful subset of women, even when blood androgen levels are not elevated.

How Does Spironolactone Work for Hair Loss?

Spironolactone can interfere with androgen activity in several ways. Most importantly for hair loss, it acts as an androgen receptor antagonist. This reduces the ability of testosterone and DHT to activate androgen receptors in susceptible tissues. Spironolactone may also reduce androgen production to some degree, although changes in circulating androgen levels are variable and are not required for the medication to have antiandrogen activity at the tissue level.

This makes its mechanism different from finasteride and dutasteride. Finasteride and dutasteride inhibit 5 alpha reductase and reduce the formation of DHT. Spironolactone primarily interferes with the effect of androgens at the receptor level. It also retains its original aldosterone blocking and diuretic effects, which explains many of its nonhair related adverse effects.

Does Spironolactone Lower DHT?

Not in the same way that finasteride or dutasteride do. Spironolactone is not primarily a 5 alpha reductase inhibitor. Its principal antiandrogen action is receptor blockade, along with effects on androgen production.

A woman therefore does not need to demonstrate a dramatic fall in serum DHT for spironolactone to have biological activity. This also means that spironolactone and 5 alpha reductase inhibitors should not be treated as interchangeable drugs simply because all of them can be described as antiandrogens.

Does a Woman Need High Testosterone for Spironolactone to Work?

No. Many women with female pattern hair loss have normal serum androgen levels. Normal testosterone does not necessarily mean that scalp follicles are unaffected by androgen signaling. Follicular sensitivity, local hormone metabolism, androgen receptor activity and other biological pathways can differ independently of a routine blood testosterone measurement.

Older studies of women treated with oral antiandrogens also failed to demonstrate that baseline serum androgen levels reliably predicted who would respond. Spironolactone can therefore be considered in selected women with female pattern hair loss even when standard androgen measurements are normal. That does not mean hormone testing has no value. Women with clinical evidence of androgen excess deserve appropriate evaluation.

When Should Androgen Excess Be Investigated?

Female pattern hair loss by itself does not prove that a woman has a hormonal disorder. However, certain findings make evaluation for androgen excess more important. These can include significant facial or body hair growth, persistent or severe acne, irregular menstrual cycles, infertility, rapid onset hair loss or other evidence of virilization.

Polycystic ovary syndrome, or PCOS, is one common cause of hyperandrogenism in women. Less commonly, adrenal or ovarian disorders can produce substantial androgen excess. A woman developing rapidly progressive hair loss together with new deepening of the voice, marked facial hair growth, increased muscularity or other significant virilization deserves prompt medical evaluation rather than simply being placed on a hair loss medication.

When an endocrine disorder is suspected, it is generally preferable to perform the appropriate evaluation before beginning systemic antiandrogen therapy. Spironolactone can alter menstrual patterns and improve acne or hirsutism, potentially masking some of the clinical clues used to evaluate hyperandrogenism.

Does Oral Spironolactone Actually Work for Female Pattern Hair Loss?

The available evidence supports benefit, but it is important to describe the strength of that evidence accurately. For many years, support for spironolactone consisted primarily of clinical experience, observational studies and relatively small trials. The evidence has improved.

A systematic review and meta analysis found improvement in approximately 57 percent of women overall, with higher response rates in studies using spironolactone as part of combination therapy than in studies of monotherapy. However, the included studies differed substantially in patient populations, doses, treatment duration and accompanying therapies. The pooled percentage should therefore not be interpreted as an exact probability that any individual woman will respond.

Nor does the higher response rate reported in combination studies prove that combination treatment is inherently superior, because these studies were heterogeneous and were not designed as direct randomized comparisons of spironolactone alone against combination treatment. The most useful conclusion is that spironolactone can stabilize or improve female pattern hair loss in a meaningful proportion of appropriately selected women, but individual response varies considerably.

What Did the Classic Long Term Study Show?

One of the best known earlier studies followed 80 women with biopsy confirmed female pattern hair loss for at least 12 months. Forty women received spironolactone 200 mg daily and 40 received the antiandrogen cyproterone acetate.

When the two antiandrogen groups were evaluated together, approximately:

• 44 percent showed visible hair regrowth
• 44 percent showed no clear change in hair density
• 12 percent continued to lose hair

There was no significant difference between the two antiandrogen treatment groups. The study was open label and did not include an untreated placebo group, so it cannot provide the same level of evidence as a modern randomized placebo controlled trial. It nevertheless demonstrated an important principle. For progressive pattern hair loss, stabilization itself can represent meaningful treatment success.

What Does the Newer Placebo Controlled Evidence Show?

A randomized double blind trial published in 2025 evaluated spironolactone 100 mg daily in 48 premenopausal women between 21 and 45 years of age. All participants also used topical minoxidil 3 percent twice daily. Women received either spironolactone or placebo for 24 weeks.

Both groups improved because both were receiving minoxidil. The spironolactone group had numerically greater average increases in terminal hair count and hair diameter. However, the quantitative between group differences did not clearly establish statistical superiority. The difference in terminal hair count approached but did not reach conventional statistical significance.

The strongest positive finding came from global photographic assessment. Thirty eight percent of women receiving spironolactone had moderate to marked improvement compared with 9 percent receiving placebo, a statistically significant difference. The study therefore provides useful evidence that spironolactone can add benefit to topical minoxidil in premenopausal women. It was still a small 24 week pilot study and should not be treated as definitive proof of the ideal dose, long term response rate or magnitude of benefit.

Mild transient elevations in potassium were also observed in a small number of participants in both groups. The values normalized on repeat testing without treatment. This small finding does not overturn the much larger safety literature in healthy younger women, but it reinforces that low risk does not mean zero risk.

What Does the 2026 Randomized Monotherapy Trial Show?

Newer evidence also comes from a 2026 randomized double blind trial involving 204 women with female pattern hair loss. Women received either spironolactone 100 mg daily or bicalutamide 50 mg daily as monotherapy for 24 weeks. One hundred eighty eight women completed the study.

Women receiving spironolactone demonstrated measurable increases in hair count at both the frontal and vertex scalp. Average hair count increased by approximately 3.1 hairs per square centimeter at the frontal site and 3.1 hairs per square centimeter at the vertex. Bicalutamide produced greater improvement in several trichoscopic measurements, including hair count and shaft diameter. However, the investigators did not find significant between treatment differences in several of the broader clinical endpoints.

This study gives us useful modern evidence that spironolactone monotherapy can produce measurable improvement. It does not establish an exact response rate because there was no placebo group, and the trial lasted only 24 weeks.

What Does the Longer 2026 Comparative Evidence Show?

A separate 2026 retrospective study followed 187 women receiving spironolactone or bicalutamide for 24 months. Among the women who completed follow up, approximately 54 percent of those in the spironolactone group improved by at least one Sinclair grade compared with approximately 37 percent of those receiving bicalutamide.

That longer term result differs from the 24 week randomized trial, which favored bicalutamide on several trichoscopic measurements. The studies should not be viewed as contradictory proof that one medication is superior.

The 24 month study was retrospective rather than randomized, and more than 90 percent of women in both groups were also taking oral minoxidil. Some were receiving additional hair loss treatments. It therefore cannot establish that spironolactone alone produced the improvement or that spironolactone is definitively superior to bicalutamide.

Taken together, the studies show that both drugs have measurable antiandrogen activity in women with female pattern hair loss, while comparative efficacy remains unsettled.

How Effective Is Spironolactone in Real Clinical Practice?

Real world results vary. A 2020 retrospective study of 79 women treated with spironolactone used an average dose of approximately 100 mg daily, with individual doses ranging from 25 to 200 mg. Some women received spironolactone alone while others used additional treatments. Clinical improvement was documented in many patients, and spironolactone was generally well tolerated.

As with most retrospective hair loss research, it is difficult to separate the effect of spironolactone from other simultaneous treatments in patients receiving combination therapy. The practical experience accumulated over several decades is nevertheless consistent with the controlled evidence.

Some women experience meaningful thickening. Some primarily stabilize. Some experience little visible change.

What Dose of Spironolactone Is Used for Hair Loss?

There is no FDA approved spironolactone dose for female pattern hair loss. Published studies have used daily doses ranging from approximately 25 mg to 200 mg. Historically, many hair loss studies used 100 to 200 mg daily.

Modern clinical practice often uses a broader range. Some physicians begin with lower doses and increase treatment depending on response, blood pressure, age, other medications and tolerability. Lower doses such as 25 mg are also used when spironolactone is combined with another medication, particularly low dose oral minoxidil.

There is no convincing evidence that every woman needs 100 or 200 mg to benefit. Likewise, the existence of lower dose regimens does not establish that 25 mg will adequately control hair loss in every patient. The appropriate dose is individualized.

Does a Higher Dose Work Better?

Possibly for some women, but the relationship has not been defined well enough to create a simple dose response rule. Historically, higher doses have often been used when greater antiandrogen activity was desired. The 2026 24 month retrospective spironolactone and bicalutamide study also found a signal favoring spironolactone doses above 100 mg in its dose stratified analysis.

That finding is interesting, but it does not prove that increasing a woman from 50 or 100 mg to 150 or 200 mg will improve her hair. The study was not a randomized dose ranging trial, nearly all participants were also receiving oral minoxidil, and other treatment differences could have influenced the result.

Higher spironolactone exposure can also produce more menstrual disturbance, breast symptoms, dizziness, blood pressure effects and electrolyte concerns. Modern hair loss treatment should not be based on automatically escalating to the largest dose used in older studies or assuming that greater antiandrogen exposure is always better. The goal is to find an exposure that provides adequate long term control with acceptable tolerability.

How Long Does Spironolactone Take to Work for Hair Loss?

Spironolactone is not a rapid hair growth treatment. Hair follicle cycling occurs slowly. A reduction in excessive shedding may sometimes be noticed before a visible improvement in density, but meaningful assessment generally requires at least six months.

For many women, six to twelve months provides a more realistic period for evaluating whether the treatment is stabilizing or improving pattern hair loss. The classic antiandrogen study evaluated women after at least 12 months, and newer long term observational data extend to 24 months.

Stopping after several weeks because the scalp does not look different is usually too early to judge efficacy. Standardized photography and objective measurement of density, hair shaft diameter or follicular miniaturization can be much more useful than casual visual comparison.

Does Spironolactone Regrow Hair or Mainly Prevent Further Loss?

It can do both. Some women experience visible thickening and increased density. Others primarily experience stabilization.

For progressive female pattern hair loss, preventing continued miniaturization can be extremely important even if dramatic regrowth does not occur. Maintenance should not automatically be mistaken for treatment failure. As with most medical hair loss therapies, follicles that remain viable but miniaturized have a better chance of responding than follicles that have become profoundly miniaturized over many years.

Does Spironolactone Work on the Frontal Scalp?

It can. Female pattern hair loss often produces thinning through the central and frontal scalp rather than the classic receding pattern seen in many men. The 2026 randomized trial specifically measured both frontal and vertex sites and documented increased hair counts in women receiving spironolactone at both locations.

This does not mean spironolactone can recreate a hairline where follicles have been lost or severely miniaturized for years. It means that miniaturizing frontal follicles can respond to antiandrogen treatment.

Does Spironolactone Cause an Initial Shed?

A predictable initial shedding phase has not been established as a routine effect of spironolactone. Women may experience fluctuations in shedding while beginning treatment, particularly when spironolactone is started with minoxidil or when another treatment is changed. But a dramatic shed should not automatically be interpreted as proof that spironolactone is working.

Female hair shedding can also result from telogen effluvium, illness, nutritional deficiency, thyroid disease, medication changes, hormonal changes or progression of the underlying pattern hair loss. Persistent or substantial new shedding deserves evaluation.

Does Spironolactone Have to Be Continued?

For female pattern hair loss, benefit is generally treatment dependent. Spironolactone does not permanently remove a woman’s biological susceptibility to follicular miniaturization. If the medication is providing meaningful antiandrogen control and treatment is stopped, the underlying process can resume.

The timing varies among individuals. This does not mean spironolactone has made the hair dependent on the drug. It means the medication was controlling part of an ongoing process.

What Are the Most Common Side Effects of Spironolactone?

The adverse effects most relevant to women taking spironolactone for hair loss include:

• Menstrual irregularity or spotting
• Breast tenderness
• Increased urination
• Dizziness or lightheadedness
• Lower blood pressure
• Fatigue
• Headache
• Nausea or gastrointestinal discomfort
• Changes in electrolyte balance

The frequency depends heavily on dose, age, underlying health, other medications and how adverse effects are measured. Most dermatologic patients tolerate spironolactone reasonably well, but tolerability should not be assumed simply because it is widely prescribed.

How Common Are Menstrual Changes?

Menstrual changes are among the most common adverse effects in premenopausal women. They can include spotting, shorter cycles, irregular bleeding or missed periods.

In the 2025 randomized trial using spironolactone 100 mg daily, menstrual irregularities occurred in approximately 38 percent of women receiving spironolactone. Most events were mild. Two women discontinued because of concern about menstrual changes, and menstrual cycles returned to normal after treatment was stopped.

Rates in ordinary clinical practice may be lower or higher depending on dose and whether the patient is also taking hormonal contraception.

Can Spironolactone Affect Fertility?

Spironolactone is not known to cause permanent infertility in women. However, it can alter menstrual cycling and may delay or interfere with ovulation in some women while the medication is being taken.

For that reason, a woman actively trying to conceive should not approach spironolactone as an ordinary long term hair loss medication. Women undergoing fertility treatment, being evaluated for infertility or being evaluated for a suspected hormonal disorder should make sure the reproductive or endocrine specialist knows that spironolactone is being used.

Because the medication can alter menstrual patterns and improve acne or hirsutism, it can also make some features of PCOS or other androgen related conditions less obvious during evaluation.

Can Birth Control Be Used With Spironolactone?

Yes. Hormonal contraception is commonly used alongside spironolactone in premenopausal women. There can be more than one reason.

Reliable contraception helps prevent pregnancy while a woman is receiving an antiandrogen. Hormonal contraception can also reduce spironolactone related menstrual irregularity in some women. However, oral contraceptives have their own risks and contraindications and are not appropriate for everyone.

Contraceptives containing drospirenone deserve particular attention because drospirenone itself has antimineralocorticoid activity and can affect potassium regulation. Current prescribing information for drospirenone containing contraceptives recommends potassium monitoring in certain women taking other medications that can raise potassium.

That does not mean drospirenone and spironolactone cannot be used together. They are commonly prescribed together in appropriate patients. It means the complete medication and risk profile should be considered rather than assuming that all contraceptive formulations are interchangeable.

Does Spironolactone Lower Blood Pressure?

It can. Spironolactone is an antihypertensive medication. A woman taking it for hair loss can therefore experience lower blood pressure, dizziness, lightheadedness or orthostatic symptoms when standing.

Many healthy women experience little meaningful blood pressure change at dermatologic doses. A study of 185 women taking 25 to 200 mg daily for alopecia found that average systolic blood pressure declined by less than 1 mmHg and average diastolic blood pressure was essentially unchanged. Five women developed a systolic blood pressure below 90 mmHg.

This supports the clinical observation that meaningful hypotension is uncommon in appropriately selected women, but it can occur. Risk can be greater in women who already have low blood pressure, are dehydrated, take other blood pressure lowering drugs or use low dose oral minoxidil. Persistent dizziness, fainting or symptomatic low blood pressure should not simply be accepted as the price of hair treatment.

Does Spironolactone Increase Potassium?

It can. This is one of the most important medical considerations with spironolactone. Spironolactone causes the kidneys to retain potassium.

Excess potassium in the blood is called hyperkalemia. Severe hyperkalemia can interfere with normal electrical activity of the heart and can become medically dangerous. The risk is not the same for every patient.

How Common Is Hyperkalemia in Young Healthy Women?

In otherwise healthy younger women, clinically significant hyperkalemia appears to be uncommon. A large study of 974 healthy young women taking spironolactone for acne found a hyperkalemia rate of approximately 0.72 percent, essentially the same as the background rate in similar women not taking the medication.

This and similar research led many dermatologists to question the value of frequent routine potassium testing in healthy younger women with normal kidney function who are not taking interacting medications. Modern dermatology guidelines for acne have also moved away from routine potassium monitoring in otherwise healthy patients without risk factors.

That evidence comes largely from young acne populations and should not be generalized to every woman taking spironolactone for hair loss. Female pattern hair loss affects women across a much wider age range.

Does Hyperkalemia Risk Increase With Age?

Yes. This becomes particularly relevant in hair loss practice because female pattern hair loss becomes more common with age.

A 2026 study evaluated 398 women age 45 and older taking spironolactone for dermatologic conditions. Hyperkalemia occurred in approximately 10 percent overall. The rate was approximately 8 percent among women ages 45 to 64 and approximately 22 percent among women 65 and older.

Women 65 and older who also had medical conditions that predisposed them to elevated potassium had the highest rate, approximately 28 percent. Most episodes were mild and asymptomatic.

This was a dermatology population rather than a study limited specifically to female pattern hair loss, so the percentages should not be interpreted as precise hair loss treatment risks. The larger point is more important. The very low hyperkalemia rates observed in healthy women in their twenties and thirties should not simply be extrapolated to older hair loss patients.

Does Everyone Need Potassium Testing?

There is no single monitoring approach appropriate for every woman using spironolactone for hair loss. Current U.S. prescribing information for spironolactone’s FDA approved indications instructs clinicians to check potassium within approximately one week of initiation or dose adjustment and regularly thereafter.

That labeling was developed for the medical conditions for which spironolactone is FDA approved, including heart failure, hypertension, edema and hyperaldosteronism. Dermatology practice is different.

Studies involving healthy younger women, particularly women treated for acne, have found very low rates of clinically significant hyperkalemia. Dermatology guidelines therefore do not recommend routine potassium monitoring in every healthy young patient without risk factors. There is no separate FDA monitoring protocol specifically for female pattern hair loss.

Hair loss patients also span a much broader age range than most acne populations. Monitoring becomes increasingly important in women who are older, have impaired kidney function, have heart disease, hypertension, diabetes, a history of elevated potassium or take other medications that can increase potassium.

Baseline kidney function, potassium level and medication history become particularly important as these risk factors accumulate. The correct approach is risk based monitoring, not the assumption that every woman requires the same laboratory schedule and not the opposite assumption that potassium testing is unnecessary for everyone.

What Medications Can Increase the Risk of High Potassium?

Important interactions include medications and supplements that can increase serum potassium or reduce kidney function. These can include:

• Potassium supplements
• Potassium containing salt substitutes
• ACE inhibitors
• Angiotensin receptor blockers
• Other potassium sparing diuretics
• Eplerenone
• Certain nonsteroidal anti inflammatory drugs
• Heparin and low molecular weight heparin
• Trimethoprim, including trimethoprim containing antibiotic combinations
• Other medications that alter kidney handling of potassium

Spironolactone is specifically contraindicated with eplerenone. Trimethoprim deserves particular attention because it is contained in commonly prescribed antibiotics and can increase potassium.

Patients should not begin potassium supplements or switch to potassium based salt substitutes simply because they believe they are healthy products while taking spironolactone. A complete medication and supplement review matters.

What About Kidney Disease?

Kidney function is important because spironolactone and its effects on potassium depend heavily on renal physiology. Women with impaired kidney function have a greater risk of hyperkalemia and other complications.

Spironolactone is contraindicated in patients who already have hyperkalemia and requires particular caution when renal function is reduced. A woman with known kidney disease should not approach spironolactone for hair loss as though it were a routine cosmetic medication.

What About Addison’s Disease?

Spironolactone is contraindicated in patients with Addison’s disease. Addison’s disease already disrupts adrenal hormone and electrolyte regulation.

Blocking aldosterone activity further can create significant electrolyte problems. This is uncommon in ordinary hair loss practice but belongs in a complete safety discussion.

What About Liver Disease?

Liver disease is not a single uniform condition, but significant hepatic disease can materially change the safety of spironolactone. Current prescribing information gives particular warnings for patients with cirrhosis and ascites because sudden changes in fluid and electrolyte balance can worsen hepatic encephalopathy and neurological function.

Clearance of spironolactone and its metabolites can also be reduced in cirrhosis. Rare cases of clinically significant liver injury have been reported after spironolactone use.

A history of mild or stable liver abnormalities is not automatically equivalent to a contraindication, but women with substantial liver disease should have the decision individualized by the physician managing their medical condition rather than treating spironolactone as a routine cosmetic medication.

Can Spironolactone Affect Sodium or Other Electrolytes?

Yes. Although potassium receives the most attention, spironolactone can also contribute to low sodium and other electrolyte or metabolic abnormalities.

Current prescribing information describes possible hyponatremia, low magnesium, low calcium, changes in acid base balance, elevated blood glucose and elevated uric acid. Clinically important abnormalities are much more likely in medically complex patients than in healthy younger women using dermatologic doses. This is another reason monitoring decisions should be individualized.

Can Spironolactone Cause Breast Tenderness or Enlargement?

Yes. Breast and nipple tenderness can occur in women. Spironolactone can also produce breast enlargement.

These effects reflect its hormonal activity. They are usually reversible after dose adjustment or discontinuation. Persistent new breast symptoms should still be medically evaluated rather than automatically attributed to spironolactone.

Does Spironolactone Increase Breast Cancer Risk?

Available human evidence is reassuring, but it cannot establish that the risk is absolutely zero. Concerns about cancer arose partly because high dose animal studies identified tumors in several organs in rats. Current prescribing information continues to discuss those animal findings.

A large systematic review and meta analysis involving more than 4.5 million people found no statistically significant increase in breast cancer among spironolactone users. However, the certainty of evidence for breast cancer was rated very low because the evidence was observational and the populations studied were generally much older than the typical dermatologic patient.

Current human evidence therefore does not support the claim that ordinary spironolactone use has been shown to increase breast cancer risk, while observational evidence cannot prove complete absence of risk.

Can Spironolactone Cause Sexual Side Effects?

It can affect sexual function, although this is discussed more often in men than in women. Current prescribing information includes decreased libido among reported reproductive adverse effects.

In women, changes in sexual function can be difficult to attribute to a single factor because hormone levels, menstrual changes, contraception, mood, other medications and underlying health can all contribute. Sexual symptoms should be taken seriously if they emerge during treatment, but there is not a well established percentage of women using spironolactone for hair loss who experience reduced libido.

Why Isn’t Oral Spironolactone Commonly Used for Male Pattern Hair Loss?

Systemic spironolactone can block androgen signaling throughout the body. In men this can produce unwanted antiandrogen effects including gynecomastia, breast tenderness, reduced libido, erectile dysfunction and other hormonal effects.

In a major heart failure trial using a mean spironolactone dose of only about 26 mg daily, approximately 9 percent of men developed gynecomastia. The risk increases with dose. Hair loss regimens in women have historically used doses considerably higher than that.

For this reason, oral spironolactone is generally not used as routine treatment for male androgenetic alopecia. Men have better established hair loss treatments that do not generally produce the same degree of systemic androgen receptor blockade.

What About Topical Spironolactone?

Topical spironolactone has been investigated as an attempt to produce local antiandrogen activity while reducing systemic exposure. The evidence is much smaller and less standardized than the evidence for oral spironolactone. Small studies have used different concentrations and vehicles, with mixed results.

There is currently no FDA approved topical spironolactone product for hair loss in the United States. Topical spironolactone used for hair loss is therefore generally supplied through compounded or other non FDA approved formulations. Concentration, vehicle, stability, penetration and systemic exposure cannot automatically be assumed to be equivalent from one compounded formulation to another.

Older pharmacologic research and small clinical studies suggest that topical administration may produce substantially less systemic exposure than oral treatment. That is not the same as proving that systemic absorption or systemic effects are impossible. Claims that a topical antiandrogen is completely local or cannot enter the bloodstream should therefore be viewed cautiously unless the specific formulation has actually been studied.

The AHLA discusses Topical Spironolactone for Hair Loss separately because topical and systemic exposure should not be treated as equivalent. For a more detailed review of the evidence, formulations, systemic absorption, safety and regulatory issues, see the AHLA’s Topical Spironolactone for Hair Loss page.

Can Spironolactone Be Combined With Topical Minoxidil?

Yes. This is a common treatment strategy. The medications act through different mechanisms.

Spironolactone addresses androgen signaling. Minoxidil functions primarily as a hair growth stimulant. The 2025 randomized trial demonstrated that adding spironolactone 100 mg to topical minoxidil produced greater photographic improvement than topical minoxidil with placebo over 24 weeks.

Earlier randomized research has also reported greater increases in hair density when oral spironolactone was added to topical minoxidil compared with topical minoxidil alone. Combination therapy can therefore be biologically and clinically reasonable. It does not mean that every woman with female pattern hair loss requires both medications.

Can Spironolactone Be Combined With Low Dose Oral Minoxidil?

Yes, and this has become increasingly common in clinical practice. The combination is attractive because the drugs approach hair loss through different mechanisms.

Spironolactone may also help counteract some of the fluid retention associated with oral minoxidil because spironolactone is a diuretic. There is now emerging observational evidence supporting that possibility, but it has not been established in large randomized trials.

Both medications can also affect blood pressure. That means the combination is not simply two hair medications added together without physiological consequences.

What Does the Evidence Show for Spironolactone With Oral Minoxidil?

An early observational study followed 100 women with female pattern hair loss who received oral minoxidil 0.25 mg together with spironolactone 25 mg daily. Hair shedding and hair loss severity improved during 12 months of treatment. Average blood pressure decreased modestly. No hyperkalemia was reported in that cohort.

The study was uncontrolled, so it could not determine how much benefit came from minoxidil and how much came from spironolactone. More recent research has evaluated larger populations and a much wider range of doses.

What Did the 2026 Combination Safety Study Show?

A 2026 study evaluated 432 adult women using low dose oral minoxidil together with spironolactone for hair loss. The average spironolactone dose at the time an adverse effect occurred was approximately 88 mg daily, while the average oral minoxidil dose was approximately 1.8 mg daily. Adverse effects were documented in approximately 38 percent of patients.

The most common were:

• Hypertrichosis, approximately 12 percent
• Dizziness, lightheadedness or orthostatic symptoms, approximately 12 percent

Most adverse effects were managed in the outpatient setting, and treatment was not changed in nearly half of cases. Women taking additional blood pressure altering medications had a substantially greater likelihood of orthostatic symptoms.

This is a useful reminder that spironolactone and oral minoxidil are both systemic drugs. Their combination can be effective and practical, but blood pressure and the rest of the patient’s medication regimen matter.

Can Spironolactone Reduce Oral Minoxidil Related Edema?

Possibly. Fluid retention and edema are recognized adverse effects of oral minoxidil. Because spironolactone promotes sodium and water excretion, clinicians have long had a physiological reason to suspect that it might reduce this problem.

Newer observational research in women with female pattern hair loss has reported a lower risk of low dose oral minoxidil related edema when spironolactone was used. This is useful emerging evidence, but it is not equivalent to a randomized trial proving that spironolactone will prevent edema in every patient.

Spironolactone should not automatically be added simply to cancel out an adverse effect from another medication without considering whether the entire regimen is appropriate.

Can Spironolactone Reduce Oral Minoxidil Hypertrichosis?

Possibly, but this remains an emerging observation. Spironolactone is used to treat hirsutism, while oral minoxidil can cause unwanted facial and body hair growth.

A small 2024 retrospective study found lower rates of hypertrichosis among women taking low dose oral minoxidil together with spironolactone than among women taking oral minoxidil alone. The difference in that small study was not statistically significant.

A much larger 2026 study found an association between simultaneous initiation of spironolactone and oral minoxidil and a lower likelihood of hypertrichosis. That finding is interesting, but the research was retrospective and does not prove that spironolactone reliably prevents minoxidil related hypertrichosis.

Spironolactone Versus Finasteride or Dutasteride in Women

All three medications can be used off label as antiandrogen strategies for selected women with female pattern hair loss. They do not work the same way.

Spironolactone blocks androgen receptor activity and has additional hormonal and diuretic effects. Finasteride and dutasteride reduce the conversion of testosterone into DHT. There is not enough high quality comparative evidence to declare one universally superior for women.

A small randomized study comparing topical minoxidil plus spironolactone with topical minoxidil plus finasteride reported greater overall improvement with the spironolactone combination over a relatively short treatment period, although subgroup findings and study design limit broad conclusions.

A separate retrospective study comparing low dose oral minoxidil combined with spironolactone against low dose oral minoxidil combined with finasteride or dutasteride found no statistically significant difference in the major hair measurements.

Treatment selection therefore depends on age, pregnancy potential, evidence of androgen excess, prior response, tolerability and medical history. There is no justification for automatically escalating from one antiandrogen to another simply because a drug produces greater DHT suppression or is described as more potent.

Spironolactone Versus Bicalutamide

Bicalutamide is another androgen receptor antagonist increasingly studied for female pattern hair loss. A 2026 randomized double blind trial comparing bicalutamide 50 mg with spironolactone 100 mg found greater improvement in several objective trichoscopic measurements with bicalutamide after 24 weeks. However, broader clinical outcomes did not significantly differ between the groups during the short study.

A separate 24 month retrospective study published later in 2026 found the opposite direction on its principal clinical measure. Approximately 54 percent of women receiving spironolactone improved by at least one Sinclair grade compared with approximately 37 percent of women receiving bicalutamide. That longer study also found an exploratory signal favoring spironolactone doses above 100 mg.

Those results need to be interpreted cautiously. The 24 month study was not randomized, more than 90 percent of participants were also receiving oral minoxidil, and some were receiving additional treatments. It therefore cannot prove that spironolactone monotherapy was superior or that doses above 100 mg are inherently more effective.

Bicalutamide also has a different safety profile, including important concerns involving liver toxicity and laboratory monitoring. Current comparative evidence is therefore insufficient to declare either medication universally superior. Spironolactone has much longer dermatologic experience and a different safety and monitoring profile.

Can Spironolactone Be Used in Postmenopausal Women?

Yes. Postmenopausal women can be appropriate candidates for spironolactone. Pregnancy prevention is no longer an issue after established menopause, which removes one major concern associated with antiandrogen treatment.

At the same time, potassium and kidney related risks become more important with age. Older women are more likely to have reduced kidney function, hypertension, diabetes or other medications that affect potassium and blood pressure. So while reproductive safety becomes less complicated, medical monitoring can become more important.

Spironolactone and Pregnancy

Spironolactone should generally be avoided during pregnancy. Because it blocks androgen activity, there is concern that fetal exposure could interfere with normal sexual differentiation of a developing male fetus.

Animal studies have demonstrated feminization and other reproductive effects in male offspring at sufficiently high exposures. Human pregnancy data are limited and have not demonstrated a clear pattern of major birth defects, but the available information is not sufficient to dismiss the biological concern.

Current prescribing information advises avoiding spironolactone during pregnancy or counseling a pregnant patient about the potential risk to a male fetus. For hair loss treatment, where therapy is elective rather than medically necessary for maternal survival, pregnancy prevention deserves particular attention.

What Should Happen if a Woman Wants to Become Pregnant?

A woman planning pregnancy should discuss spironolactone with the prescribing physician before attempting conception. The medication should not simply be continued because it has been tolerated well.

Many dermatology references recommend discontinuing spironolactone at least one month before attempting conception. That interval is a precautionary clinical recommendation rather than a washout period established through pregnancy trials.

The physician can determine an appropriate discontinuation strategy and substitute treatments when appropriate. Hair loss treatment during pregnancy requires a different risk benefit calculation from treatment in a nonpregnant patient.

Can Spironolactone Be Used While Breastfeeding?

The breastfeeding data are more reassuring than the pregnancy data. Spironolactone itself has not been detected in human milk in the limited available measurements, while small amounts of its active metabolite canrenone have been found.

The amount transferred to the infant is expected to be low, and available reports have not identified adverse effects in breastfed infants. The National Library of Medicine’s LactMed database considers spironolactone generally acceptable during breastfeeding based on the limited available evidence.

However, long term infant data are limited, and current prescribing information notes that long term effects on the breastfed infant and effects on milk production are not known. Hair loss treatment during the postpartum period should also begin with the correct diagnosis because postpartum telogen effluvium is extremely common and is not the same condition as progressive female pattern hair loss.

A breastfeeding woman considering spironolactone should discuss the decision with her physician.

Can Spironolactone Be Used in Teenagers?

Spironolactone is used by dermatologists in selected adolescents for conditions such as acne and androgen related disorders. However, FDA prescribing information states that safety and effectiveness have not been established for pediatric patients for the approved indications.

Hair loss in a teenager deserves a careful diagnosis. Diffuse shedding, nutritional problems, traction, autoimmune disease, endocrine disorders and other conditions can resemble early pattern hair loss. A long term antiandrogen should not be prescribed simply because a young patient reports thinning.

Does Spironolactone Cause Weight Loss?

Spironolactone is not a weight loss medication. Because it is a diuretic, it can cause the body to excrete sodium and water. Some people may therefore notice a temporary change in scale weight related to fluid balance.

That should not be confused with loss of body fat. Using more spironolactone in an attempt to lose weight would increase the risk of dehydration, low blood pressure and electrolyte abnormalities without providing a legitimate fat loss benefit.

How Should Spironolactone Be Taken With Food?

Spironolactone can be taken with or without food, but consistency matters. Food can substantially increase spironolactone absorption. Current prescribing information reports that food can nearly double overall drug exposure compared with fasting conditions.

For that reason, patients are advised to establish a consistent pattern regarding meals. That does not necessarily mean every patient must take spironolactone with food. It means repeatedly taking it under very different conditions can change drug exposure. Patients should follow the instructions provided with their prescription and use the medication consistently.

Are There Other Important Drug Interactions?

Yes. In addition to drugs that increase potassium, spironolactone can interact with several medications. It can reduce the renal clearance of lithium and increase the risk of lithium toxicity.

Nonsteroidal anti inflammatory drugs can affect kidney function and can alter spironolactone’s diuretic and antihypertensive effects. Spironolactone can interfere with some laboratory assays used to measure digoxin. There are also specific interactions with medications such as abiraterone and mitotane.

Most women taking spironolactone for hair loss will never use many of these medications. The broader point is important. A medication prescribed for hair loss still needs to be included in the patient’s complete medical and medication history.

Who Should Be Especially Cautious With Spironolactone?

Additional caution is appropriate in women with:

• Kidney impairment
• Previous hyperkalemia
• Addison’s disease
• Low blood pressure or recurrent fainting
• Significant heart disease
• Significant liver disease
• Use of medications that increase potassium
• Use of multiple blood pressure lowering medications
• Pregnancy or plans for pregnancy
• A history of significant adverse effects from antiandrogen therapy

Older age does not automatically prevent spironolactone use, but it changes the importance of kidney function, potassium and medication interactions.

What Should Be Evaluated Before Starting Spironolactone for Hair Loss?

The first priority is establishing the correct diagnosis. Not every woman with diffuse thinning has female pattern hair loss. Telogen effluvium, iron deficiency, thyroid disease, autoimmune disorders, inflammatory scalp disease, traction and medication related hair loss can produce similar complaints.

The medical history should also address blood pressure, kidney function, pregnancy potential, menstrual history, symptoms of androgen excess and current medications and supplements. If the clinical picture suggests PCOS or another endocrine disorder, appropriate hormonal evaluation is best considered before spironolactone begins masking acne, hirsutism or menstrual patterns.

Depending on the patient’s age and medical history, baseline potassium and renal function may be appropriate. For older patients or women with medical comorbidities or interacting medications, laboratory monitoring takes on substantially greater importance.

The goal is not simply to prescribe an antiandrogen. It is to determine whether an antiandrogen actually makes sense for the patient’s diagnosis and risk profile.

What Should Someone Ask Before Starting Spironolactone?

Useful questions include:

• What is my actual diagnosis?
• Is there evidence that androgens may be contributing to my hair loss?
• What dose are we using and why?
• How long should I remain on treatment before judging the result?
• How will we determine whether the medication is stabilizing my hair loss?
• Do I need baseline potassium or kidney function testing?
• Will I need repeat blood testing?
• Could any of my medications or supplements raise potassium or lower blood pressure?
• What should I do if I develop irregular bleeding, breast tenderness, dizziness or other adverse effects?
• What is the plan if I want to become pregnant?
• Should spironolactone be used alone or with minoxidil?

The answers should be individualized rather than based on a one size fits all hair loss protocol.

The AHLA Perspective

Oral spironolactone occupies an important place in the treatment of female pattern hair loss. It is not FDA approved for hair loss, and the clinical evidence is not as extensive as the evidence supporting topical minoxidil. But spironolactone is also not an experimental fringe treatment. It has decades of dermatologic use, a substantial clinical literature and increasingly useful randomized evidence.

The newest studies reinforce several important points. Spironolactone can improve or stabilize female pattern hair loss. It can add benefit to minoxidil. It can produce measurable improvement when used alone. And it can be combined with low dose oral minoxidil in appropriately selected women.

At the same time, female pattern hair loss should not simply be treated as male pattern hair loss occurring in a woman. The role of androgens is more variable. Many women with female pattern hair loss have normal circulating androgen levels. The decision to use systemic antiandrogen therapy should therefore be based on the complete clinical picture rather than a simplistic assumption that every woman with thinning has excessive DHT.

Spironolactone also deserves to be treated as a real systemic medication. It can alter blood pressure. It can cause menstrual irregularity and breast symptoms. It can raise potassium. Pregnancy exposure is a legitimate concern.

The very low hyperkalemia risk documented in healthy younger women should not be automatically applied to women in their fifties, sixties or seventies, particularly those with kidney disease, medical comorbidities or other medications affecting potassium. That distinction matters because the population seeking treatment for female pattern hair loss spans a much broader age range than the young women in many dermatology safety studies.

Newer studies also should not be used as an excuse for automatic treatment escalation. A retrospective signal suggesting greater improvement with higher spironolactone exposure does not establish that every patient should receive more than 100 mg.

Likewise, adding topical minoxidil, oral minoxidil or another antiandrogen can be useful when there is a clinical reason to do so, but combination therapy should not become an exercise in accumulating as many hair loss medications as possible.

The objective is to establish the diagnosis, preserve viable follicles, identify the lowest effective and sustainable treatment strategy and monitor the patient according to her actual medical risk rather than according to a generic hair loss protocol.

Used for: Female Pattern Baldness

Selected References

1. U.S. National Library of Medicine. Spironolactone Tablets: Full Prescribing Information. Includes FDA approved indications, contraindications, hyperkalemia, renal impairment, pregnancy, lactation, drug interactions and pharmacokinetics. DailyMed Prescribing Information
2. Sinclair R, Wewerinke M, Jolley D. Treatment of Female Pattern Hair Loss With Oral Antiandrogens. British Journal of Dermatology. 2005;152:466 to 473. PubMed
3. Aleissa M, et al. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta Analysis. 2023. PubMed
4. Efficacy and Safety of Oral Spironolactone for Female Pattern Hair Loss in Premenopausal Women: A Randomized Double Blind Placebo Controlled Parallel Group Pilot Study. 2025. PubMed
5. Jha AK, Zeeshan M, Singh A, Ankad BS. Spironolactone Versus Bicalutamide in Female Pattern Hair Loss: A Randomized Clinical Trial. Clinical and Experimental Dermatology. 2026;51:1406 to 1411. PubMed
6. Spironolactone Versus Bicalutamide for Female Pattern Hair Loss: A 24 Month Unicenter Retrospective Comparative Study of Effectiveness and Safety. Dermatology and Therapy. 2026. PubMed
7. Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatology. 2015;151:941 to 944. doi:10.1001/jamadermatol.2015.34. PubMed
8. Gregoire S, Dewey E, Sanchez K, et al. Hyperkalemia Incidence in Females Over 45 Years Old on Spironolactone for Dermatologic Conditions: A Retrospective Cohort Study. Journal of the American Academy of Dermatology. 2026;94:1671 to 1678. PubMed
9. Sinclair RD. Female Pattern Hair Loss: A Pilot Study Investigating Combination Therapy With Low Dose Oral Minoxidil and Spironolactone. International Journal of Dermatology. 2018;57:104 to 109. doi:10.1111/ijd.13838. PubMed
10. Dewey E, Salloum L, Gregoire S, et al. Safety and Tolerability of Combination Oral Spironolactone and Low Dose Oral Minoxidil for Hair Loss in Adult Females: A Retrospective Cohort Study. Journal of the American Academy of Dermatology. 2026;94:1679 to 1685. doi:10.1016/j.jaad.2026.02.003. PubMed
11. Bommareddy K, Hamade H, Lopez Olivo MA, Wehner M, Tosh T, Barbieri JS. Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta Analysis. JAMA Dermatology. 2022;158:275 to 282. doi:10.1001/jamadermatol.2021.5866. PubMed
12. U.S. National Library of Medicine. Spironolactone. Drugs and Lactation Database, LactMed. LactMed